PATHOLOGY & ONCOLOGY RESEARCHVol. 5 No. 2, 1999

 Article

Epidermal Growth Factor Receptor, Somatostatin and Bcl-2 in Human Pancreatic Tumor Xenografts

An Immunohistochemical Study

Attila ZALATNAI

First Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Budapest, Hungary

 

Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor. Pathology & Oncology Research, Vol 5, Nr 2, 146-151, 1999

Key words: pancreas tumor; xenogaft; somatostatin; bcl-2


Received: Jan 22, 1999; accepted: Apr 10, 1999
Correspondence: Attila ZALATNAI, First Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Üllôi út 26. Budapest H-1085, Hungary; Tel: +36-1-2661638, Fax: +36-1-3171074; E-mail: zalatnai@korb1.sote.hu

Click here to get the full-text version in PDF!
ad